MOLOGEN and ONCOLOGIE: Global assignment and codevelopment agreement relating to MOLOGEN’s lead compound lefitolimod
The biopharmaceutical company MOLOGEN AG signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN’s lead compound lefitolimod to ONCOLOGIE…